Molecure reçoit une recommandation favorable de l’IDMC pour poursuivre l’essai clinique KITE sans modification du protocole de l’étude (programme de développement OATD-01)

Phase 2positiveOATD-01Positive

AI Analysis

Summary

Molecure S.A. received a favorable IDMC recommendation to continue its Phase II KITE clinical trial of OATD-01, a first-in-class CHIT1 inhibitor for active pulmonary sarcoidosis, without protocol modifications.

Clinical Trial Data

Phase

Phase II

Outcome Details

Independent Data Monitoring Committee recommended continuation of Phase II KITE clinical trial without protocol modifications

Importance:6/10

Sentiment:

0.65

clinical-trialIDMC-favorable-recommendationCHIT1-inhibitorsarcoidosisPoland

Related Companies

$ACTI.ST $GILD

Read the original article

Published by GlobeNewswire Clinical Studies on August 4, 2026 2:04 PM

Read Original